GAO Questions FDA's Handling Of Surrogate Endpoints
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA should develop guidance delineating when it would withdraw products that have been cleared under the accelerated approval mechanism, according to a report from the Government Accountability Office